MDT Medtronic (MDT) Q3 FY26 earnings call
Medtronic delivered strong Q3 FY26 results, achieving its highest organic revenue growth in 10 quarters, driven by robust performance in Cardiac Ablation Solutions and new product launches across its portfolio. The company is actively building new markets for generational growth drivers like PFA, Symplicity Spyral, Altaviva, and Hugo, while also addressing areas needing improvement such as Structural Heart. Management remains committed to durable revenue and high single-digit EPS growth in FY27, leveraging innovation and strategic investments.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
MDT operating KPIs by quarter
| KPI | This call Jan 2026 Q3 FY26 | Apr 2026 Q4 FY26 | Jul 2026 Q1 FY27 | Change vs prior quarter |
|---|---|---|---|---|
| Installed base Touch Surgery | 1,000+This quarter, Touch Surgery installations increased over 20% sequentially and have now surpassed 1,000 systems globally.Source: earnings call transcript | 1,400+And our Touch Surgery Digital Ecosystem, well, it continues to represent a clear advantage with over 1,400 installations, up 30% plus sequentially.Source: earnings call transcript | 1,500+Today, Touch Surgery is used in more than 1,500 operating rooms globally, supporting AI-powered insights, collaboration and workflows.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.